Medical emergency?Emergency? Call 911. Nearest emergency roomsNearest ERs

Drug company (FDA labeler)

American Regent, Inc.

NDC labeler code: 0517

What is a labeler?

The company whose name is on the package and in the FDA’s National Drug Code (NDC) Directory. It may make the medicine itself or sell medicine made by another company. The first part of every NDC code identifies the labeler.

Official FDA data only

Products, approvals and recalls come from the FDA (NDC Directory, Drugs@FDA, enforcement reports). Recalls are linked to this company by the NDC labeler code on the recalled product.

Questions about your medicine: ask your doctor or pharmacist. In an emergency, call 911.

At a glance

64Products (NDC)

Prescription medicines

FDA applications for these products

  • NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
  • ANDA: Abbreviated New Drug Application: how a generic version is approved.
ApprovedApplicationMedicineSponsor
September 6, 2024ANDA217192 Epinephrine
EPINEPHRINE
Am Regent
June 21, 2024ANDA218314 Sodium phosphate, monobasic, monohydrate and sodium phosphate, dibasic anhydrous
SODIUM PHOSPHATES
Am Regent
October 2, 2023ANDA216274 Potassium phosphate, monobasic potassium phosphate, dibasic injection,
POTASSIUM PHOSPHATES
Am Regent
July 27, 2022NDA211875 Paclitaxel
PACLITAXEL
Am Regent
May 26, 2022ANDA216120 Atropine
ATROPINE SULFATE
Am Regent
August 3, 2020NDA212593 Vasopressin
VASOPRESSIN
Am Regent
July 2, 2020NDA209376 Trace elements injection 4
MULTRYS, TRALEMENT
Am Regent
September 10, 2019NDA212097 Glucagon
GVOKE HYPOPEN, GVOKE KIT, GVOKE PFS
Xeris
July 18, 2019NDA209377 Zinc sulfate
ZINC SULFATE
Am Regent
April 30, 2019NDA209379 Selenious acid
SELENIOUS ACID
Am Regent
July 6, 2018ANDA207568 Epinephrine
EPINEPHRINE
Am Regent
July 27, 2017ANDA209088 Calcium chloride
CALCIUM CHLORIDE 10%
Am Regent
February 17, 2017ANDA208353 Dicyclomine hydrochloride
DICYCLOMINE HYDROCHLORIDE
Am Regent
April 8, 2016NDA204630 Methylene blue
PROVAYBLUE
Provepharm Sas
July 25, 2013NDA203565 Ferric carboxymaltose
INJECTAFER
Am Regent
April 22, 2013ANDA202561 Chlorothiazide
CHLOROTHIAZIDE SODIUM
Am Regent
March 20, 2012ANDA201741 Olanzapine
OLANZAPINE
Am Regent
January 19, 2010ANDA090920 Estradiol valerate
ESTRADIOL VALERATE
Am Regent
November 17, 2009ANDA090534 Nicardipine
NICARDIPINE HYDROCHLORIDE
Am Regent
July 31, 2009ANDA090747 Betamethasone sodium phosphate and betamethasone acetate
BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE
Am Regent
November 24, 2008ANDA090193 Methylergonovine maleate
METHYLERGONOVINE MALEATE
Am Regent
December 14, 2007ANDA078368 Fomepizole
FOMEPIZOLE
Am Regent
June 22, 2001ANDA075861 Levocarnitine
LEVOCARNITINE
Am Regent
November 6, 2000NDA021135 Iron sucrose
VENOFER
Am Regent
June 30, 1997ANDA040136 Hydralazine hydrochloride
HYDRALAZINE HYDROCHLORIDE
Am Regent
Show the other 8 applications
ApprovedApplicationMedicineSponsor
July 28, 1995ANDA072489 Acetylcysteine
ACETYLCYSTEINE
Am Regent
July 28, 1995ANDA072547 Acetylcysteine
ACETYLCYSTEINE
Am Regent
October 24, 1988ANDA072123 Droperidol
DROPERIDOL
Am Regent
May 24, 1988ANDA072034 Nitroglycerin
NITROGLYCERIN
Am Regent
December 1, 1987ANDA071192 Aminocaproic acid
AMINOCAPROIC ACID
Luitpold
July 23, 1986ANDA089335 Glycopyrrolate
GLYCOPYRROLATE
Am Regent
August 27, 1981ANDA087408 Hydroxyzine
HYDROXYZINE HYDROCHLORIDE
Am Regent
April 26, 1972ANDA080737 Cyanocobalamin
CYANOCOBALAMIN
Am Regent

The sponsor is the company that holds the FDA application; it can differ from the labeler.

Recall timeline

2026

  1. August 11, 2026 · Class I · Ongoing · D-0865-2026 · Epinephrine

    Presence of Particulate Matter and Lack of Assurance of Sterility. Particulate matter identified as nylon, cellulosic, acrylic, polyethylene and glass and broken and leaking vials.

    Epinephrine Injection, USP, 30 mg/30 mL (1mg/mL), 30 mL-Multiple-Dose Vial, Rx Only, For Intravenous Infusion, intramuscular and Subcutaneous Use, AMERICAN REGENT INC., SHIRLEY, NY 11967. NDC 0517-3030-01

  2. July 24, 2026 · Class II · Ongoing · D-0799-2026 · Trace elements injection 4

    Presence of Particulate Matter: Product contaminated with particulate matter identified as hair, glass and/or paraformaldehyde

    Multrys (Trace Elements Injection 4, USP), For intravenous infusion, packaged in a) 1 mL Single-Dose Vial (NDC 0517-9302-01), and b) 25x1 mL Single-Dose Vials (NDC 0517-9302-25) Rx Only, AMERICAN REGENT, INC., SHIRLEY, N

  3. July 24, 2026 · Class II · Ongoing · D-0797-2026 · Acetylcysteine

    Presence of Particulate Matter: Product contaminated with particulate matter identified as hair, glass and/or paraformaldehyde

    ACETYLCYSTEINE SOLUTION, USP, 20% (200 mg/mL), packaged in a) 4 mL Vial NOT FOR INJECTION (NDC 0517-7604-01), and b) 25x4 mL Vials NOT FOR INJECTION (NDC 0517-7604-25), Rx only, AMERICAN REGENT, INC., SHIRLEY, NY 11967.

  4. July 24, 2026 · Class II · Ongoing · D-0795-2026 · Atropine

    Presence of Particulate Matter: Product contaminated with particulate matter identified as hair, glass and/or paraformaldehyde

    Atropine Sulfate injection, USP, 1 mg/mL, For intravenous Use, Sterile, packaged in a) 1 mL Single-Dose Vial (NDC 0517-1001-01), and b) 25x1 mL Single-Dose Vial (NDC 0517-1001-25), Rx only, AMERICAN REGENT INC., SHIRLEY,

  5. July 24, 2026 · Class II · Ongoing · D-0794-2026 · Aminocaproic acid

    Presence of Particulate Matter: Product contaminated with particulate matter identified as hair, glass and/or paraformaldehyde

    AMINAOCAPROIC ACID INJECTION, USP, 250 mg/mL (5 g/20 mL), packaged in a) 20 mL MULTIPLE DOSE VIAL FOR IV INFUSION (NDC 0517-9120-01), and b) 25x20 mL MULTIPLE DOSE VIALS (NDC 0517-9120-25), Rx Only, American Regent, Inc.

  6. July 24, 2026 · Class II · Ongoing · D-0792-2026 · Cyanocobalamin

    Presence of Particulate Matter: Product contaminated with particulate matter identified as hair, glass and/or paraformaldehyde

    Cyanocobalamin injection USP, 1,000 mcg/mL, For IM or SC Use Only, packaged in a) 1 mL Multi-Dose Vial (NDC 0517-0031-01), and b) 25x1 mL Multi-Dose Vials (NDC 0517-0031-25) Rx only, AMERICAN REGENT, INC., SHIRLEY, NY 11

  7. July 24, 2026 · Class II · Ongoing · D-0796-2026 · Acetylcysteine

    Presence of Particulate Matter: Product contaminated with particulate matter identified as hair, glass and/or paraformaldehyde

    ACETYLCYSTEINE SOLUTION, USP, 10% (100 mg/mL), packaged in a) 4 mL Vial NOT FOR INJECTION (NDC 0517-7504-01), and b) 25x4 mL Vials NOT FOR INJECTION (NDC 0517-7504-25), Rx Only, AMERICAN REGENT, INC., SHIRLEY, NY 11967.

  8. July 24, 2026 · Class II · Ongoing · D-0801-2026 · Trace elements injection 4

    Presence of Particulate Matter: Product contaminated with particulate matter identified as hair, glass and/or paraformaldehyde

    Tralement (trace elements injection 4*, USP), packaged in a) 1mL Single Dose vials (NDC 0517-9305-01) and b) 5x1mL Single Dose vials (NDC 0517-9305-25), Rx only, AMERICAN REGENT, INC., SHIRLEY, NY 11967.

  9. July 24, 2026 · Class II · Ongoing · D-0798-2026 · Selenious acid

    Presence of Particulate Matter: Product contaminated with particulate matter identified as hair, glass and/or paraformaldehyde

    Selenious Acid Injection, USP 12 mcg/2 mL (6 mcg/2mL), For intravenous use, packaged in a) 2mL Single-Dose Vial (NDC 0517-6502-01), and b)10x2mL Single-Dose Vial (NDC 0517-6502-10), Rx Only, AMERICAN REGENT, INC., SHIRLE

  10. July 24, 2026 · Class II · Ongoing · D-0793-2026 · Cyanocobalamin

    Presence of Particulate Matter: Product contaminated with particulate matter identified as hair, glass and/or paraformaldehyde

    Cyanocobalamin injection USP, 10,000 mcg/10 mL (1,000 mcg/mL), For IM or SC Use Only, packaged in a) 10 mL Multi-Dose Vial (NDC 0517-0032-01) and b) 25x10 mL Multi-Dose Vials (NDC 0517-0032-25), Rx Only, AMERICAN REGENT,

Show the 6 older recalls

2026

  1. July 24, 2026 · Class II · Ongoing · D-0791-2026 · Nitroglycerin

    Presence of Particulate Matter: Product contaminated with particulate matter identified as hair, glass and/or paraformaldehyde

    Nitroglycerin injection, USP, 50 mg/10 mL (5 mg/mL), packaged in a) 10 mL vials (NDC 0517-4810-01), b) 25x10mL vials (NDC 0517-4810-25) RX only, AMERICAN REGENT, INC., Shirley, NY 11967.

  2. April 16, 2026 · Class III · Ongoing · D-0494-2026 · Levocarnitine

    Labeling: Missing Label

    Levocarnitine Injection, USP, 1 g/5 mL (200 mg/mL), 5 mL Single-Dose Vial, For intravenous use, Rx Only, American Regent, Inc., Shirley, NY 11967. NDC: 0517-1045-01

2025

  1. April 18, 2025 · Class II · Ongoing · D-0399-2025 · Nicardipine

    Lack of sterility assurance: Product leakage around the vial neck, which could potentially result in a lack of sterility assurance.

    niCARdipine Hydrochloride Injection, USP, 25 mg/10 mL (2.5 mg/mL), 10 mL Single Dose Vial, Rx Only, American Regent, Inc., Shirley, NY 11967. NDC carton: 0517-0735-10 / NDC Vial: 0517-0735-01]

2024

  1. November 11, 2024 · Class II · Ongoing · D-0082-2025 · Iron sucrose

    Presence of Particulate Matter: Potential for glass delamination from the vials.

    Venofer (iron sucrose) Injection, USP 100 mg Elemental Iron per 5 mL (20 mg/mL), 5 mL Single-Dose Vials, Rx Only, For Intravenous Use Only, American Regent, Inc. Shirley, NY 11967, NDC: 0517-2340-01 (vial), NDC: 0517-234

  2. May 13, 2024 · Class II · Terminated · D-0507-2024 · Vasopressin

    Subpotent product in addition to having out-of-specification results for impurities.

    Vasopressin Injection, USP, 200 Units per 10 mL (20 Units per mL), 10 mL Multiple-Dose Vial, Rx only, For Intravenous Infusion, American Regent, Inc., Shirley, NY 11967, NDC 0517-1030-01

2019

  1. March 28, 2019 · Class I · Terminated · D-1248-2019 · Betamethasone sodium phosphate and betamethasone acetate, Bupivacaine hydrochloride, Lidocaine

    Presence of Particulate Matter: One vial was found to contain a hair.

    Lidocaine HCl Injection, USP 1 % 50 mg/5 mL (10 mg/mL), 5mL vial, Rx only, Mrd. in India for: AuroMedics Pharna LLC. E Windsor, NJ 08520 NDC 55150-162-05

What do the recall classes mean?

Class I: The most serious type: there is a reasonable chance that using the product will cause serious health problems or death.
Class II: Using the product may cause temporary or medically reversible health problems, or the chance of serious problems is remote.
Class III: Using the product is not likely to cause health problems (for example a labeling or packaging issue).

Sources

  1. NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
  2. Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
  3. Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026

FDA Enforcement Report search → · Report an error →